Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Novo Nordisk is conducting the SELECT-LIFE study, officially titled ‘SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication.’ The study aims to assess the long-term effects of semaglutide on participants who were part of the SELECT Cardiovascular Outcomes Trial. This research holds significance as it evaluates the prolonged impact of anti-obesity medication on cardiovascular health.
Intervention/Treatment: The study is observational and non-interventional, meaning no specific treatment is administered. Participants from the SELECT trial will transition to the SELECT-LIFE study, where they will be surveyed about their health every six months for up to ten years.
Study Design: SELECT-LIFE is a prospective cohort study. Participants are not allocated to different groups, and there is no masking involved. The primary purpose is to observe long-term health outcomes without any study-specific treatments.
Study Timeline: The study began on September 1, 2023, and is currently recruiting participants. The last update was submitted on July 15, 2025. These dates are crucial as they mark the study’s progress and ongoing data collection.
Market Implications: This update could positively influence Novo Nordisk’s stock performance and investor sentiment by showcasing the company’s commitment to long-term research in obesity treatment. It may also impact competitors focusing on similar therapeutic areas, emphasizing the importance of long-term data in the industry.
The SELECT-LIFE study is ongoing, with further details available on the ClinicalTrials portal.